High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors
Table 3
Characteristics of primary and secondary AI resistance subgroups.
Total ()
AI primary resistance ()
AI secondary resistance ()
%
%
Estrogen receptor
Positive
17
9
100
8
100
NA
Negative
0
0
0
0
0.0
Progesterone receptor
Positive
13
6
67
7
86
0.576
Negative
4
3
33
1
14
HER2
Positive
3
3
33
0
0
0.206
Negative
14
6
67
8
100
History of therapy
Tamoxifen
3
2
22
1
13
1.000
Chemotherapy
8
7
78
1
13
0.015
Trastuzumab
2
2
22
0
0
0.471
Previous HT lines
One line
7
4
44
3
38
1.000
Two lines
10
5
56
5
62
Site of metastasis
Liver
7
4
44
3
38
1.000
Lung
12
4
44
8
100
0.029
Bone
10
6
67
4
50
0.637
Pleura
2
1
11
1
13
1.000
Peritoneum
1
1
11
0
0
1.000
Soft tissue
7
5
56
2
25
0.335
AI: aromatase inhibitor; NA: not applicable; HER2: human epidermal growth factor receptor 2; HT: hormone therapy.
